A Phase 2 interventional study of SAR444656 (KT-474) and Placebo in Atopic Dermatitis, sponsored by Sanofi. Terminated at 22 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 17th largest by enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2023, is one of 8 in phase 2, and was the 27th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:
Sanofi · Sites in Qatar, Saudi Arabia, United Arab Emirates
Ages 12+
Sanofi · Sites in United States, Canada, China and 6 more countries
Ages 12+
Sanofi · Sites in Italy
Ages 6 mo–17 yrs
Sanofi
Ages 12+
Sanofi
Ages 18+
By country, each count listing its studies:
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 8
First in 2006; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is below the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 112 across the 28 interventional studies, 266 across the 15 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
6 of the studies in Dermatitis, Atopic by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT06837454SanofiFrench Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | 2027-05-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies in Dermatitis, Atopic by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who were inadequately controlled with topical therapies or for whom such topical therapies were inadvisable and who were candidates for systemic therapy.
Participants were randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo.
Participants who met inclusion/exclusion criteria were stratified for randomization by severity of AD (moderate [baseline EASI score \<22] versus severe [baseline EASI score ≥22]).
The total duration of study was approximately 24 weeks, including 1 to 4 weeks for screening, 16 weeks for double-blind study treatment and 4 weeks for follow-up.
The criteria were revised on the registry on Nov 3, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo matched to SAR444656 tablet orally from Day 1 to Week 16.
Drug: Placebo
Participants received SAR444656 Dose Level 1 tablet orally from Day 1 to Week 16. Dose Level 1 is the highest dose level.
Drug: SAR444656 (KT-474)
Participants received SAR444656 Dose Level 2 tablet orally from Day 1 to Week 16. Dose Level 2 is the lower dose level.
Drug: SAR444656 (KT-474)
Oral Tablet
Oral Tablet
Percent Change From Baseline in Eczema Area and Severity Index at Week 16
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (erythema \[E\], induration/papulation \[I\], excoriation \[X\] and lichenification \[L\]) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of body surface area (BSA) is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.
Time frame: Baseline (Day 1) and Week 16
Percentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 16
The vIGA-AD is an Investigator-led assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe). Higher vIGA-AD scores indicate more severe disease. Percentage of participants with a score of 0 or 1 and a reduction from baseline of \>=2 points at Week 16 are presented here. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline (Day 1) and Week 16
Percentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-75 was defined as reduction of EASI score by \>=75% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline (Day 1) and Week 16
Absolute Change From Baseline in Eczema Area and Severity Index at Week 16
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.
Time frame: Baseline (Day 1) and Week 16
Percentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-50 was defined as reduction of EASI score by \>=50% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline (Day 1) and Week 16
Percentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-90 was defined as reduction of EASI score by \>=90% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
Time frame: Baseline (Day 1) and Week 16
Change From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16
The BSA affected by AD is assessed by the Investigator for each section of the body. Each body region is weighted using the 'rule of nines': head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%); reported as a percentage of all major body sections combined. Baseline was defined as last available value before the first dose of double-blind study drug.
Time frame: Baseline (Day 1) and Week 16
Percentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 16
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization. Percentages are rounded off to tenth decimal place.
Time frame: Baseline (Day 1) and Week 16
Percent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.
Time frame: Baseline (Day 1) and Week 16
Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.
Time frame: Baseline (Day 1) and Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (TEAESIs) and TEAEs Leading to Study Drug Discontinuation
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. A TEAE was an AE that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) was one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.
Time frame: From first dose of study drug (Day 1) up to 20 weeks
Serum Concentrations of SAR444656
Blood samples were collected at specified timepoints to determine serum concentration of SAR444656.
Time frame: Pre-dose, 2, 4 and 7 hours post-dose at Weeks 0 and 2; pre-dose and 7 hours post-dose at Weeks 1, 4 and 16
The study was conducted at 20 centers in 4 countries from 09-Nov-2023 to 20-Nov-2025. A total of 70 participants were randomized. Dosing information (dose levels and frequency) has not been disclosed as it is considered as commercially confidential information. Dose levels decrease from 1 to 3, with Dose Level 1 being the highest dose and Dose Level 3 the lowest dose.
| Milestone | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Started | 28 | 28 | 14 |
| Completed | 19 | 20 | 10 |
| Not completed | 9 | 8 | 4 |
| Withdrew: Adverse event | 1 | 3 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 |
| Withdrew: Poor compliance to protocol | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 1 |
| Withdrew: Other | 2 | 0 | 2 |
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (erythema \[E\], induration/papulation \[I\], excoriation \[X\] and lichenification \[L\]) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of body surface area (BSA) is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.
| percent change | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index at Week 16 | -31.58 ± 9.08 | -39.94 ± 10.35 | -34.16 ± 14.35 |
The vIGA-AD is an Investigator-led assessment scale used to determine severity of AD and clinical response to treatment. It is based on a 5-point scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe). Higher vIGA-AD scores indicate more severe disease. Percentage of participants with a score of 0 or 1 and a reduction from baseline of \>=2 points at Week 16 are presented here. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percentage of Participants With Validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) of 0 or 1 and a Reduction From Baseline of >=2 Points at Week 16 | 10.7 | 25.0 | 42.9 |
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-75 was defined as reduction of EASI score by \>=75% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percentage of Participants Achieving 75% Reduction From Baseline in Eczema Area and Severity Index (EASI-75) at Week 16 | 17.9 | 25.0 | 42.9 |
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. Baseline was defined as last available value before the first dose of double-blind study drug.
| score on a scale | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Absolute Change From Baseline in Eczema Area and Severity Index at Week 16 | -7.65 ± 10.34 | -9.68 ± 11.28 | -9.40 ± 15.55 |
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-50 was defined as reduction of EASI score by \>=50% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percentage of Participants Achieving 50% Reduction From Baseline in Eczema Area and Severity Index (EASI-50) at Week 16 | 46.4 | 42.9 | 42.9 |
EASI is an Investigator-assessed validated tool to measure extent (area) and severity of AD based on 4 disease characteristics (E, I, X and L) in 4 different body areas using 4-point scale: 0 (absent) to 3 (severe). Extent of involvement of AD in 4 body regions: head/neck, trunk, UE and LE is assessed. For each region, percentage of BSA is converted to area score: 0=no eruption, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-100%. EASI score is calculated as: (E+I+X+L) x area score. Total EASI score is the weighted total of region EASI using weights 10% (head/neck), 20% (UE), 30% (trunk) and 40% (LE); ranges from 0 to 72 and higher scores indicate increased extent and severity of AD. EASI-90 was defined as reduction of EASI score by \>=90% from baseline. Baseline was defined as last available value before the first dose of double-blind study drug. Percentages are rounded off to the tenth decimal place.
| percentage of participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percentage of Participants Achieving 90% Reduction From Baseline in Eczema Area and Severity Index (EASI-90) at Week 16 | 10.7 | 25.0 | 14.3 |
The BSA affected by AD is assessed by the Investigator for each section of the body. Each body region is weighted using the 'rule of nines': head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%); reported as a percentage of all major body sections combined. Baseline was defined as last available value before the first dose of double-blind study drug.
| percent BSA | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Change From Baseline in Percent Body Surface Area Affected by Atopic Dermatitis at Week 16 | -8.17 ± 10.92 | -13.73 ± 16.33 | -10.74 ± 21.82 |
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization. Percentages are rounded off to tenth decimal place.
| percentage of participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percentage of Participants With >=4-Point Reduction From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale (PP-NRS) at Week 16 | 7.1 | 14.8 | 42.9 |
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.
| percent change | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Percent Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16 | -16.39 ± 32.26 | -10.93 ± 36.39 | -28.19 ± 43.68 |
The PP-NRS is a validated single item 0-10 numerical rating scale assessing peak pruritus (itch) associated with AD during the past 24 hours. The participant is asked about the severity of his/her pruritus on a 0 to 10 scale, where 0=no itch and 10=worst itch imaginable. Higher scores indicate more severe disease. The weekly average PP-NRS score was calculated as the average of 7 days preceding the actual visit day of measurement with a minimum of 4 completions in their daily diary. Baseline was defined as the average of all available daily non-missing scores obtained during the 7 days prior to randomization.
| score on a scale | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus-Numeric Rating Scale at Week 16 | -0.90 ± 1.68 | -0.85 ± 2.24 | -2.53 ± 3.23 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or any other medically important event. A TEAE was an AE that developed, worsened or became serious during the TE period. An AESI was an AE (serious or non-serious) was one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required.
| Participants | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Any TEAE | 10 | 20 | 8 |
| Any TESAE | 0 | 2 | 0 |
| Any TEAESI | 0 | 2 | 0 |
| Any TEAE Leading to Study Drug Discontinuation | 1 | 3 | 0 |
Blood samples were collected at specified timepoints to determine serum concentration of SAR444656.
| nanogram per milliliter | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|
| Week 0: Pre-dose | 0.00 ± 0.00 | 0.00 ± 0.00 |
| Week 0: 2 hours post-dose | 6.08 ± 5.89 | 2.72 ± 3.15 |
| Week 0: 4 hours post-dose | 8.50 ± 8.05 | 4.65 ± 5.28 |
| Week 0: 7 hours post-dose | 9.90 ± 8.69 | 5.39 ± 5.64 |
| Week 1: Pre-dose | 9.76 ± 6.53 | 4.04 ± 3.20 |
| Week 1: 7 hours post-dose | 16.13 ± 8.69 | 7.70 ± 5.45 |
| Week 2: Pre-dose | 8.86 ± 6.55 | 4.03 ± 2.35 |
| Week 2: 2 hours post-dose | 14.38 ± 10.75 | 6.98 ± 3.79 |
| Week 2: 4 hours post-dose | 16.94 ± 11.88 | 7.88 ± 4.67 |
| Week 2: 7 hours post-dose | 15.60 ± 9.45 | 8.38 ± 3.78 |
| Week 4: Pre-dose | 8.60 ± 7.90 | 3.44 ± 2.61 |
| Week 4: 7 hours post-dose | 13.28 ± 8.36 | 7.19 ± 5.28 |
| Week 16: Pre-dose | 6.68 ± 8.61 | 2.65 ± 1.84 |
| Week 16: 7 hours post-dose | 19.17 ± 10.53 | 3.73 ± 2.25 |
Collected over AEs were collected from first dose of study drug (Day 1) up to 20 weeks. All-cause mortality (deaths) was collected from first dose of study drug (Day 1) up to study termination, up to approximately 106 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 0/28 (0%) | 4/28 (14.3%) |
| SAR444656 Dose Level 1 | 0/28 (0%) | 2/28 (7.1%) | 11/28 (39.3%) |
| SAR444656 Dose Level 2 | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| Event | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| Abdominal PainGastrointestinal disorders | 0/28 | 1/28 | 0/14 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/28 | 1/28 | 0/14 |
| Maternal Exposure During PregnancyInjury, poisoning and procedural complications | 0/28 | 1/28 | 0/14 |
| Event | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 |
|---|---|---|---|
| HeadacheNervous system disorders | 0/28 | 7/28 | 2/14 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 4/28 | 0/28 | 2/14 |
| InfluenzaInfections and infestations | 0/28 | 2/28 | 0/14 |
| NasopharyngitisInfections and infestations | 1/28 | 1/28 | 1/14 |
| Urinary Tract InfectionInfections and infestations | 0/28 | 2/28 | 0/14 |
| Bowen's DiseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/28 | 0/28 | 1/14 |
| DizzinessNervous system disorders | 0/28 | 1/28 | 1/14 |
| MicrosleepNervous system disorders | 0/28 | 0/28 | 1/14 |
| SyncopeNervous system disorders | 0/28 | 0/28 | 1/14 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/28 | 0/28 | 1/14 |
The efficacy population included all randomized participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 | Total |
|---|---|---|---|---|
| Mean | 34.6 ± 12.2 | 39.7 ± 16.2 | 43.9 ± 15.0 | 38.5 ± 14.7 |
| Sex: Female, Male(Participants) | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 | Total |
|---|---|---|---|---|
| Female | 16 | 18 | 8 | 42 |
| Male | 12 | 10 | 6 | 28 |
| Race/Ethnicity, Customized(Participants) | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 | Total |
|---|---|---|---|---|
| Caucasian | 22 | 20 | 12 | 54 |
| Black or African American | 5 | 6 | 1 | 12 |
| Asian | 0 | 2 | 0 | 2 |
| Not Reported | 0 | 0 | 1 | 1 |
| Eczema Area and Severity Index (EASI)(score on a scale) | Placebo | SAR444656 Dose Level 1 | SAR444656 Dose Level 2 | Total |
|---|---|---|---|---|
| Mean | 21.6 ± 11.0 | 23.1 ± 9.5 | 21.8 ± 7.6 | 22.2 ± 9.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2023 to primary completion in Oct 2025, 23 months.
Results were first posted in Nov 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tipasertideg